April 06, 2021
Article
Some drugs commonly used for psoriasis can increase the risk of cardiovascular diseases, whereas other treatments can reduce the risk.
March 16, 2021
With a 1-hour infusion and lower infusion volume, oritavancin could minimize health system costs to treat these infections and improve efficiency in clinical practice.
June 18, 2020
Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23.
June 10, 2020
Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.
May 12, 2020
May 04, 2020
What is causing a patient's outbreak of psoriasis?
September 23, 2019
Top news of the day across the health care landscape.
August 13, 2019
A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.
July 30, 2019
Top news of the day from across the health care landscape.
July 11, 2019
Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.
